Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1985 2
1986 1
1987 2
1988 1
1989 3
1990 3
1992 2
1993 4
1994 4
1995 6
1996 4
1997 3
1998 3
1999 9
2000 4
2001 3
2003 2
2004 4
2005 3
2006 8
2007 16
2008 11
2009 16
2010 13
2011 14
2012 18
2013 28
2014 21
2015 28
2016 33
2017 22
2018 26
2019 24
2020 28
2021 24
2022 18
2023 14
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Growth hormone-producing pituitary gland adenoma"
Page 1
Diagnosis and Treatment of Acromegaly: An Update.
Ershadinia N, Tritos NA. Ershadinia N, et al. Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007. Mayo Clin Proc. 2022. PMID: 35120696 Review.
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion of insulin-like growth factor 1. ...Early diagnosis and adequate treatment are essential to mitigate excess mortality associated with …
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion …
Diagnosis and Treatment of Pituitary Adenomas: A Review.
Molitch ME. Molitch ME. JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699. JAMA. 2017. PMID: 28170483 Review.
Prolactinomas account for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are generally treated with the dopamine agonists cabergoline and bromocripti …
Prolactinomas account for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertility in women and los …
Molecular targets in acromegaly.
Labadzhyan A, Melmed S. Labadzhyan A, et al. Front Endocrinol (Lausanne). 2022 Dec 5;13:1068061. doi: 10.3389/fendo.2022.1068061. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36545335 Free PMC article. Review.
Molecular therapeutic targets in growth hormone (GH)-secreting adenomas range from well-characterized surface receptors that recognize approved drugs, to surface and intracellular markers that are potential candidates for new drug development. ...The degree of contr …
Molecular therapeutic targets in growth hormone (GH)-secreting adenomas range from well-characterized surface receptors that r …
Neurology of the pituitary.
Samarasinghe S, Emanuele MA, Mazhari A. Samarasinghe S, et al. Handb Clin Neurol. 2014;120:685-701. doi: 10.1016/B978-0-7020-4087-0.00047-4. Handb Clin Neurol. 2014. PMID: 24365347 Review.
Patients with pituitary adenomas can be asymptomatic or present with symptoms due to mass effect, pituitary hormone dysfunction, or both. Prolactinomas represent 40% of pituitary adenomas, the majority of which are microadenomas. Hyperfunction of gr …
Patients with pituitary adenomas can be asymptomatic or present with symptoms due to mass effect, pituitary hormone dys …
Modern approach to resistant acromegaly.
Giustina A, di Filippo L, Uygur MM, Frara S. Giustina A, et al. Endocrine. 2023 May;80(2):303-307. doi: 10.1007/s12020-023-03317-7. Epub 2023 Feb 15. Endocrine. 2023. PMID: 36790521
BACKGROUND: Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary mass, control of clinical activity and mortality with a multimodal/multidisciplinary approach. Despite significant technological and pharma …
BACKGROUND: Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary …
Pituitary Medicine From Discovery to Patient-Focused Outcomes.
Melmed S. Melmed S. J Clin Endocrinol Metab. 2016 Mar;101(3):769-77. doi: 10.1210/jc.2015-3653. Epub 2016 Feb 23. J Clin Endocrinol Metab. 2016. PMID: 26908107 Free PMC article. Review.
CONTEXT: This perspective traces a pipeline of discovery in pituitary medicine over the past 75 years. OBJECTIVE: To place in context past advances and predict future changes in understanding pituitary pathophysiology and clinical care. ...Challenges facing t …
CONTEXT: This perspective traces a pipeline of discovery in pituitary medicine over the past 75 years. OBJECTIVE: To place in context …
DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.
Ben-Shlomo A, Deng N, Ding E, Yamamoto M, Mamelak A, Chesnokova V, Labadzhyan A, Melmed S. Ben-Shlomo A, et al. J Clin Invest. 2020 Nov 2;130(11):5738-5755. doi: 10.1172/JCI138540. J Clin Invest. 2020. PMID: 32673291 Free PMC article.
Drivers of sporadic benign pituitary adenoma growth are largely unknown. Whole-exome sequencing of 159 prospectively resected pituitary adenomas showed that somatic copy number alteration (SCNA) rather than mutation is a hallmark of hormone-s …
Drivers of sporadic benign pituitary adenoma growth are largely unknown. Whole-exome sequencing of 159 prospectively re …
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors.
Bianchi A, Chiloiro S, Giampietro A, Gaudino S, Calandrelli R, Mazzarella C, Caldarella C, Rigante M, Gessi M, Lauretti L, De Marinis L, Olivi A, Pontecorvi A, Doglietto F. Bianchi A, et al. Front Endocrinol (Lausanne). 2023 May 3;14:1123267. doi: 10.3389/fendo.2023.1123267. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37206441 Free PMC article. Review.
Growth Hormone-secreting adenomas exhibits variable biological behavior and heterogeneous natural history, ranging from small adenomas and mild disease, to invasive and aggressive neoplasms with more severe clinical picture. ...To date, no clinical, laborator …
Growth Hormone-secreting adenomas exhibits variable biological behavior and heterogeneous natural history, ranging from …
Growth hormone secreting pituitary carcinomas: Case report and review of literature.
Vekaria S, Chen F, Zan E, William C, Sen C, Lebowitz R, Zagzag D, Warren FA, Brandler TC, Agrawal N. Vekaria S, et al. Growth Horm IGF Res. 2021 Oct-Dec;60-61:101430. doi: 10.1016/j.ghir.2021.101430. Epub 2021 Sep 29. Growth Horm IGF Res. 2021. PMID: 34607164 Review.
We present a case of a growth hormone (GH)-secreting pituitary carcinoma with a review of literature to better characterize this disease. ...CONCLUSION: Growth hormone (GH)-secreting pituitary carcinomas are rare and hard to distinguish f …
We present a case of a growth hormone (GH)-secreting pituitary carcinoma with a review of literature to better characte …
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G. Ilie MD, et al. J Clin Endocrinol Metab. 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. J Clin Endocrinol Metab. 2022. PMID: 36136828
Finally, SST5 IRS was higher in preoperative hyperintense compared with preoperative hypointense adenomas (P = 0.04), and most sparsely granulated and most hyperintense adenomas expressed high SST5 levels. CONCLUSION: We prospectively confirm that SST2A and adenoma granula …
Finally, SST5 IRS was higher in preoperative hyperintense compared with preoperative hypointense adenomas (P = 0.04), and most sparsely gran …
378 results